MATERIALS & METHODS

Study setting and subjects

This study provides a secondary analysis of previously reported research [16]. Subjects were consecutively recruited from the movement disorder clinics at Royal North Shore Hospital, Sydney, Australia, June 2018 to June 2019. PD patient inclusion criteria were 1) > 18 years of age, 2) a clinical diagnosis of idiopathic PD according to the UK Parkinson’s Disease Society Brain Bank Diagnostic Criteria [17], and 3) being managed by a specialist neurologist. The caregiver inclusion criteria were 1) > 18 years of age, 2) a spouse, sibling or child to their respective PD subject, 3) exhibited no clinical indication of PD on examination and 4) were subjectively “well” according to the caregiver. Approval from the local Human Research Ethics Committees was obtained, (HREC/18/HAWKE/109) and (NSPHEC 2018-LNR-009). All participants provided written informed consent to participate in the study.

Data collection

Participants completed self-administered questionnaires, in addition to providing socio-demographic, lifestyle and clinical management information. The SF-36 [12] was chosen as the common HRQoL tool and was administered on both PD patients and their caregivers to determine an individual’s perceived health status, with scales measuring each of the following eight health concepts: 1) physical functioning, 2) role limitations because of physical health problems, 3) bodily pain, 4) social functioning, 5) general mental health (psychological distress and psychological wellbeing), 6) role limitations because of emotional problems, 7) vitality (energy/fatigue) and 8) general health perceptions. Two aggregate summary scores, the Physical Component Summary (PCS) and the Mental Component Summary (MCS), are derived from the eight concepts. An additional question regarding the individual’s change in health status over the past year was asked to estimate changes in health. Each scale was scored from 0 (most disability) to 100 (least disability). PD patients completed the PDQ-39 [11], a validated measure of QoL in PD, that includes eight disease-specific scales of subjective health status: 1) mobility, 2) activities of daily living, 3) emotions, 4) social stigma, 5) social support, 6) cognition, 7) communication and 8) bodily discomfort. Each scale was scored from 0 (least affected) to 100 (most affected).

Depression was assessed by the Beck Depression Inventory (BDI), which contains 21 items on a 4-point scale from 0 (symptom absent) to 3 (severe symptoms), with a range of overall scores from 0–63 [18]. Depression was diagnosed in accordance with validated BDI cut-off criteria; > 13 for PD patients and > 9 for caregivers [19,20]. NMS were assessed by the Non-Motor Symptoms Scale (NMSS), scored between 0 (least affected) to 243 (most affected), from nine individual health domains [21]. Clinical motor assessments were performed by one neurologist during a patient’s ‘on’ state, as an objective measure of the prevailing motor function in accordance with the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale–Part III (MDS-UPDRS-III) criteria [22]. Medications were compared following standard methods for calculating daily levodopa equivalent dose (LED) [23], while rapid eye movement sleep behavior disorder (RBD) [24] and impulse control disorder (ICD) [25] were defined according to established diagnostic criteria. Other questionnaires included the Leeds Dyspepsia Questionnaire (LDQ) [26], assessing upper gastrointestinal symptoms; the Rome-IV criteria [27] and the Cleveland Constipation Scale (CCS) [28], to classify constipation severity; as well as the International Physical Activity Questionnaire (IPAQ) [29], to quantify physical activity, as described previously [16].

Statistical analysis

Two-sample, independent t-tests and chi-squared tests were used to analyze differences between continuous and categorical variables, respectively. Data normality was confirmed using the Shapiro-Wilk test. Logistic and linear regression models evaluated differences in HRQoL features between the PD and caregiver groups, as well as within the PD cohort, after controlling for demographic and clinical variables. Pearson correlations evaluated clinically relevant variables. Statistical significance was set at p < 0.05. Analysis was performed using SPSS, version 26 (IBM Corp., Armonk, NY, USA).

RESULTS

Demographic and clinical characteristics

Demographic information pertaining to the cohort studied here has been reported previously [16]. Briefly, 103 PD patients and 81 caregivers were enrolled in the study (Table 1). Over half of the PD participants were male, and two-thirds of the caregivers were female. Of the combined cohort (PD and caregivers), approximately 80% were married and identified as Caucasian, 50% had completed tertiary studies, 70% reported a self-funded income and 10% were unemployed, with no significant differences observed between the groups. Overall, 32% of PD patients compared to 4.9% of caregivers reported utilizing any support services (p < 0.001), while 60% of PD patients versus 82% of caregivers reported interest in utilizing telemedicine for their own health (p < 0.001), which posed important considerations regarding the delivery of healthcare. Over one-third of all participants identified as being prior smokers, and over 90% of participants reported daily caffeine consumption, although PD patients reported lower daily intake [2.3 (SD 1.7) vs. 3.1 (SD 1.8) cups, p = 0.003]. PD patients also reported a lower alcohol consumption compared to caregivers (70% vs. 87.7%, p = 0.003, as reported previously [16]) (Table 1).

Within the PD cohort, the mean age of symptom onset was 58.8 years (SD 13.6), and the mean duration of disease was 9.2 years (SD 6.5). A total of 10.7% were diagnosed as young onset (< 40 years), and 49.5% of patients reported late onset (> 60 years) disease (Table 2). Approximately one-third of all PD patients had either a tremor-dominant or akinetic rigid phenotype, and more than half identified troublesome motor fluctuations, particularly dyskinesias. Of the NMS, three quarters reported hyposmia, and half reported RBD [24]. Overall, 20% of PD patients displayed an ICD [25], and 16.5% of patients reported utilizing rehabilitation in the preceding 12 months, as previously reported [16]. Approximately 5% of the PD cohort was treatment-naïve, and more than 80% of patients reported medication ‘wearing off’ prior to their next dose. The utilization of standard and deviceassisted therapies, as well as the frequency and severity of chronic pain, depression, physical activity, gastrointestinal symptoms and other NMS in the PD cohort, are further outlined in Table 2.

Quality of life differences between Parkinson’s disease patients and their caregivers

Patients with PD reported significantly decreased HRQoL across all eight health concepts assessed by the SF-36 (all p < 0.001) (Table 1). The mean PCS score in the PD cohort was 51.6 (SD 22.7) compared to 79.9 (SD 17.7; p < 0.001) for the caregiver group, while the mean MCS score was 60.9 (SD 22.2) vs. 80.8 (SD 17.4; p < 0.001), respectively (Table 1). Not surprisingly, PD patients also reported a significantly greater deterioration of their health over the year prior compared to their caregivers, 38.8 (SD 21.7) vs. 50.6 (SD 16.3, p < 0.001) (Table 1), which was inferred from a cross-sectionally acquired single SF-36 question about health perception over the preceding year. The self-perceived mean 12% reduction in health change within the PD cohort correlated most significantly with indicators of disease severity, including higher daily LED (r = -0.205, p = 0.038) and higher MDS-UPDRS-III score (r = -0.248, p = 0.012), as well as a lower IPAQ score (r = 0.310, p = 0.001), higher BDI (r = -0.390, p < 0.001), higher NMSS TS (r = -0.416, p < 0.001) and a higher LDQ score (r = -0.293, p = 0.003).

Logistic regression models evaluated the significance of HRQoL severity differences between the PD and caregiver groups. Statistical significance for both the PCS and MCS scores between the groups persisted after controlling for age, sex, support services, chronic pain, depression (BDI score), physical activity, constipation (Rome-IV criteria) and upper gastrointestinal dysfunction (Wald χ² = 11.8, df = 7, p = 0.001 and Wald χ² = 4.4, df = 7, p = 0.036, respectively).

Factors influencing quality of life in Parkinson’s disease patients

The PDQ-39 Summary Index (PDQ-39 SI) (composite score of the eight health domains) demonstrated overall moderate HRQoL impairment in the PD cohort (29.2, SD 17.3). Bodily discomfort had the highest impairment associations (39.7, SD 26.8), while the lowest impairment was associated with higher social support (14.3, SD 19.3) (Table 2). Analysis of NMS by the MDS NMSS Total Score (NMSS TS) showed a mean score of 62.7 (SD 42.9), with the individual nine domain scores provided in Table 2. PD patients who were employed rather than unemployed or retired reported a better HRQoL (β = 0.203, r² = 0.084, p = 0.039), controlling for age, sex and PD duration. Not surprisingly, the 32% of individuals who required support services (of any type) reported a significantly worse HRQoL (higher PDQ-39 SI) compared to those who did not access services after controlling for age, sex and PD duration (β = 0.181, r² = 0.294, p = 0.042). A moderate correlation between the increasing use of support services and the PDQ-39 SI was also shown (r = 0.344, p < 0.001). Subjects who required any form of rehabilitation in the preceding 12-months reported a poorer HRQoL than those who did not after controlling for age, sex and PD duration (β = -0.220, r² = 0.089, p = 0.029). However, individuals with a longer disease duration reported a lower HRQoL (higher PDQ-39 SI) after controlling for age and sex (β = 0.500, r² = 0.266, p < 0.001). Interestingly, individuals reporting RBD as well as an ICD had a worse HRQoL (higher PDQ-39 SI) after controlling for age, sex and PD duration (β = -0.305, r² = 0.356, p < 0.001 and β = -0.194, r² = 0.303, p = 0.027, respectively).

Treatment influences

Increased disease severity, reflected by a higher MDS-UPDRSIII score, was associated with a worse HRQoL (higher PDQ-39 SI) after controlling for age, sex and PD duration (β = 0.429, r² = 0.423, p < 0.001), with a strong corresponding correlation (r = 0.509, p < 0.001) (Table 2). The MDS-UPDRS-III score also correlated with the NMSS TS (r = 0.414, p < 0.001). Motor control appeared to be an important predictor for HRQoL in PD, with individuals who reported dyskinesias, ‘on/off’ fluctuations and wearing off, having a lower HRQoL (higher PDQ-39 SI) after controlling for age, sex and disease duration (β = -0.267, r² = 0.318, p = 0.008; β = -0.306, r² = 0.126, p = 0.003; β = -0.250, r² = 0.103, p = 0.012, respectively). Interestingly, dyskinesias were also associated with worse NMS (higher NMSS TS) after controlling for age, sex and PD duration (β = -0.428, r² = 0.179, p < 0.001).

Individuals using catechol-O-methyl transferase (COMT) inhibitors reported a worse HRQoL (higher PDQ-39 SI) after controlling for age, sex and PD duration (β = -0.202, r² = 0.303, p = 0.028). COMT inhibitors and apomorphine infusions were also associated with higher NMSS TS after controlling for age, sex and PD duration (β = -0.250, r² = 0.101, p = 0.017; β = -0.392, r² = 0.195, p < 0.001, respectively). No associations between HRQoL and other standard and advanced therapies were observed. However, correlations were noted between individuals who required a higher LED, having worse HRQoL (higher PDQ-39 SI), higher NMSS TS and higher MDS-UPDRS-III scores (r = 0.329, p < 0.001; r = 0.295, p = 0.003; r = 0.344, p < 0.001, respectively), indicating that increased medication requirement was associated with worse HRQoL.

Lifestyle influences

Physical activity appeared to favorably predict HRQoL perceptions, with individuals who exercised more reporting a better HRQoL (lower PDQ-39 SI) and lower NMSS TS after controlling for age, sex and PD duration (β = -0.236, r² = 0.313, p = 0.012; β = -0.287, r² = 0.116, p = 0.007, respectively). Moderate correlations between the IPAQ score and PDQ-39 SI or NMSS TS were also identified (r = -0.390, p < 0.001; r = -0.260, p = 0.006, respectively). Individuals who reported chronic pain (> 3 months) were more likely to report a lower HRQoL (higher PDQ-39 SI) and higher NMSS TS after controlling for age, sex and PD duration (β = -0.310, r² = 0.358, p < 0.001; β = -0.339, r² = 0.156, p = 0.001, respectively). Pain severity scores, assessed by the Visual Analogue Scale, were also positively correlated with the PDQ-39 SI and NMSS TS (r = 0.408, p < 0.001; r = 0.346, p = 0.002, respectively). No associations with HRQoL were identified between smoking status or caffeine consumption.

Gastrointestinal influences

Individuals diagnosed with constipation according to the RomeIV criteria (score ≥ 2) or increased upper gastrointestinal dysfunction, namely indigestion and excess fullness and bloating, were noted to have a lower HRQoL (higher PDQ-39 SI) and higher NMSS TS after controlling for age, sex and PD duration (Rome IV: - β = -0.279, r² = 0.337, p = 0.002; β = -0.300, r² = 0.128, p = 0.003, respectively; LDQ: - β = 0.441, r² = 0.438, p < 0.001; β = 0.443, r² = 0.219, p < 0.001, respectively). Strong positive correlations between the PDQ-39 SI and the Rome-IV score, CCS score and LDQ score were noted (r = 0.408, p < 0.001; r = 0.487, p < 0.001; r = 0.524, p < 0.001, respectively) (Figure 1), as were relationships between the NMSS TS and the Rome-IV score, CCS score and LDQ score (r = 0.391, p < 0.001; r = 0.343, p < 0.001; r = 0.370, p < 0.001, respectively).

Mood influences

PD patients diagnosed with depression reported a lower HRQoL (higher PDQ-39 SI) and higher NMS burden (higher NMSS TS) after controlling for age, sex and PD duration (β = 0.568, r² = 0.585, p < 0.001; β = 0.527, r² = 0.320, p < 0.001, respectively). Strong correlations between the BDI score, PDQ-39 SI and NMSS TS were identified (r = 0.693, p < 0.001; r = 0.632, p < 0.001, respectively) (Figure 2).

DISCUSSION

We identified numerous clinically significant HRQoL differences across a number of demographic and clinical characteristics in patients with PD (Figure 3). Additionally, this study is one of the first to assess HRQoL in an Australian cohort of people caring for family members with PD, with notable differences between PD patients and their caregivers. PD patients reported a significantly lower HRQoL across all health concepts, as well as the aggregate PCS and MCS scores assessed by the SF-36, in line with other international studies [30]. Surprisingly, an earlier Australian study showed no differences in perceived HRQoL between PD patients and their caregivers; however, the earlier study utilized a different assessment scale, which may have incurred methodological limitations, such as a ceiling effect [4]. Interestingly, the differences between the PD and caregiver groups in our study more notably identified increased physical limitations (> 8%) compared to differences in mental impairment, derived from the PCS and MCS aggregate scores, suggesting that individuals with PD are more significantly burdened by physical limitations, prompting appropriately increased provision of health services, particularly physical therapy. Furthermore, we showed that PD patients had a considerably accelerated decline (12%) in their perceived health status in the preceding year compared to their caregivers. This decline was most associated with markers of advancing PD severity, lower physical activity, higher depression severity and increased NMS, in particular upper gastrointestinal dysfunction. Again, this highlights the importance of timely provision of comprehensive medical and rehabilitative therapies to target the above associated factors that infer the greatest detrimental influence for QoL decline in PD.

The mean PDQ-39 SI of 29.2 for this PD cohort signified moderate HRQoL impairment severity and was comparable to other Australian and international studies [6,13,14,31,32]. The mean NMSS TS of 62.7 was slightly higher than that reported by the international NMSS validation study, which had a mean score of 56.5.21 This may be due to a longer disease duration of 2.8 years for the cohort studied here. Surprisingly, there is a lack of Australian studies reporting on NMSS in PD, particularly given that an earlier study showed a strong correlation (r² = 0.7) between the NMSS and the PDQ-39 SI, supporting its validity for assessing HRQoL in PD [32]. Susceptibility to a lower HRQoL was identified in patients who were unemployed or retired, receiving any social support services or utilizing rehabilitation services, signifying a need to tailor improved social support structures for PD patients. We also showed that PD patients with RBD and ICD perceived a significantly lower HRQoL, as has been suggested previously [33]. These patients may be more vulnerable to worsening HRQoL due to potential confounded sleep and psychiatric disturbances that are observed in RBD and ICDs, although further studies examining such associations are required. Not surprisingly, clinical features suggestive of increasing disease severity were indicative of a lower HRQoL; advancing PD duration, increased MDS-UPDRS-III scores, increased daily LED, and motor complications hallmarked by the presence of ‘on/off’ fluctuations, ‘wearing off’ and particularly dyskinesias, all predicted a worse HRQoL in PD [34]. In our cohort, patients using COMT inhibitors and apomorphine infusions also reported a lower HRQoL, likely due to preferential use of these adjuvant therapies in advanced disease.

A novelty of this study is the evaluation of features beyond the PD-specific factors examined in earlier studies [4,6,13-15], with a number of important associations between physical activity, chronic pain, pain severity, gastrointestinal dysfunction and mood identified. We showed that PD patients reporting lower physical activity were more likely to perceive a lower HRQoL, with correlations to NMS severity. This finding reveals important management implications, as a low outcome expectation from exercise, a lack of time to exercise and a fear of falling are important perceived barriers to PD patients engaging in exercise [35], despite the positive impact exercise has on the global NMS burden [36]. Physical activity has also been suggested to moderate the deterioration of motor skills and depression and increase the HRQoL of PD patients, with aerobic training being most beneficial [37]. Another important modifiable risk factor for improving HRQoL in PD is chronic pain. We found a correlation between chronic pain, the severity of NMS and HRQoL, which has not been reported for Australian PD patients. However, the associations between chronic pain in PD, as well as increasing pain severity and a lower HRQoL, have been reported in other cohorts [38], with an estimated 40–80% of PD patients living with chronic pain [39]. Furthermore, the comparatively lower willingness for PD patients to utilize telemedicine for their health compared to their caregivers is rather surprising and identifies an important gap to address in the provision of quality healthcare via an online medium. The possibilities for not engaging with telemedicine include PD patients being resistant to engage with clinicians via technology, a presumed decrease in the quality of care obtained, lack of trust or confidentiality reasons, caregivers being overly enthusiastic to use telemedicine, reduced travel requirements and reduction of their own social isolation, or caregiver-related stress due to caring for their spouse. Exploring these mechanisms further is vital to developing an adaptive and integrative future telemedicine model of care for PD patients. Despite this, other literature has reported that approximately 60% of PD individuals desire to utilize telemedicine [14].

Between 60–80% of PD patients report constipation, which is known to impact a patient’s HRQoL considerably [40], although this has not previously been evaluated in an Australian cohort. We found that upper and lower gastrointestinal dysfunction was associated with a lower HRQoL and increased NMS in our PD cohort [16]. In addition to constipation, indigestion, excess fullness and bloating were also related to a lower HRQoL and higher NMS burden. These findings represent important clinical implications in the management of gastrointestinal dysfunction in PD [16].

Lastly, the negative impacts of depression on HRQoL have been extensively reported in other PD populations [41]. In this study, unsurprisingly, we confirmed that individuals with increased NMS and a lower HRQoL were more likely to be depressed. Correlations between depression and its severity with a higher NMS burden and lower HRQoL highlight the importance of considering the modification of a patient’s mood as a practical means of improving their HRQoL. However, it is uncertain whether impairment of HRQoL results in vulnerability to depression or whether depression affects the perception of HRQoL. We would suggest that both are likely contributory, given that depressed patients are more likely to report poor disability status as a reflection of their poor perception of disability [42]. Perhaps co-treatment of mood for more immediate results and other features for longer-term sustainability are needed.

While our data do not fully address some potential confounding factors, including other comorbidities and medication effects, several important known and novel HRQoL-related differences in PD patients and their caregivers were identified. The findings of this study should be interpreted in light of its limitations, which include selection bias from specialist PD clinic recruitment (i.e., over-representation of PD patients with lower HRQoL presenting for treatment) [16] and bias from the self-reporting data collected. Another consideration is that the caregivers in this study were related to patients with PD. Due to potential caregiver-related fatigue or distress, if compared to a healthy control group, the perceptible decrease in caregiver HRQoL is likely overrepresented and/or indirectly influenced. However, this was a considered limitation, given our intention to examine HRQoL changes in PD patient caregivers. Understanding what PD-related modifiable symptoms correlate with lower HRQoL for caregivers may help to target these factors and improve the lives of not only the patients, but their caregivers as well. Furthermore, our sample population was drawn from a single metropolitan area. While it has been described that PD patients from urban centers report a lower HRQoL, individuals from regional areas were more satisfied with their treatment, despite reporting a poorer understanding of their illness [14]. Significant gender-related differences have also been reported in PD, with men experiencing lower HRQoL, specifically with activities of daily living, cognition and communication compared to women [13].

In our cohort of PD patients and their caregivers, we demonstrate that individuals with PD have a significantly lower HRQoL than their caregivers, with the largest differences noted in the physical rather than mental limitations. We have also identified potential factors to target in future studies to improve the lives of patients with PD, as well as their caregivers. Unemployment or retirement, need for social support services, rehabilitation use, RBD and ICDs were all associated with a lower HRQoL in our PD cohort. Increasing disease severity, hallmarked by increasing PD duration, higher MDS-UPDRS-III, higher daily LED, motor fluctuations and in particular dyskinesias, were also reflective of a lower HRQoL. In addition, our findings suggest that PD patients with decreased physical activity, chronic pain, depression, constipation and upper gastrointestinal dysfunction are more vulnerable to a lower HRQoL. We recommend routinely screening for and optimizing the HRQoL of PD patients by treating depression and chronic pain, promoting physical activity, as well as recognizing and treating constipation and upper gastrointestinal dysfunction as part of routine clinical practice.

Notes

Conflicts of Interest

Not industry sponsored. All authors report no relevant disclosures. ML is the recipient of a RACP Research Entry Scholarship. RLD was a New South Wales Health Early-Mid Career Research Fellow. CMS is the recipient of a NHMRC Practitioner Fellowship (APP1136800).

Ethical Standard

Ethics approval was obtained from the Northern Sydney Local Health District (HREC/18/HAWKE/109) and Ramsay Health for North Shore Private Hospital (NSPHEC 2018-LNR-009) Human Research Ethics Committees. All participants provided written informed consent to participate in the study.

Author Contributions

Conceptualization: all authors. Data curation: all authors. Formal analysis: Michal Lubomski, Ryan L. Davis. Funding acquisition: all authors. Investigation: all authors. Methodology: all authors. Project administration: all authors. Resources: all authors. Software: Michal Lubomski, Ryan L. Davis. Supervision: all authors. Validation: all authors. Visualization: all authors. Writing—original draft: all authors. Writing—review & editing: all authors.

Acknowledgments

We thank Parkinson’s New South Wales for a Research Seed Grant to perform microbiome studies. We would also like to thank all our participants and Dr. Carly Oboudiyat for critically reviewing the manuscript. Not industry sponsored. All authors report no relevant disclosures.

Figure 1.

Associations between health-related quality of life and gastrointestinal dysfunction in Parkinson’s disease. Strong positive correlations between the PDQ-39 Summary Index and the RomeIV score, r = 0.408, p < 0.001; CCS score, r = 0.487, p < 0.001, and LDQ score r = 0.524, p < 0.001, were identified, suggesting that individuals with worse constipation severity (reflected by higher RomeIV scores and CCS scores) or upper gastrointestinal dysfunction (reflected by a higher LDQ score) had a higher overall PDQ-39 Summary Index, indicating a lower health-related quality of life. PDQ-39: Parkinson’s Disease Questionnaire, CCS: Cleveland Constipation Scale, LDQ: Leeds Dyspepsia Questionnaire.

Figure 2.

Associations between health-related quality of life (measured by the PDQ-39) and depression severity or non-motor symptoms in Parkinson’s disease. Strong positive correlations between the BDI score and the PDQ-39 Summary Index, r = 0.693, p < 0.001; and the NMSS TS and the PDQ-39 Summary Index, r = 0.632, p < 0.001, were identified, suggesting that individuals with worse depression severity, reflected by higher BDI scores as well as worse non-motor symptoms, suggested by a higher NMSS TS, had an overall higher PDQ-39 Summary Index, indicating a lower healthrelated quality of life. PDQ-39: Parkinson’s Disease Questionnaire, BDI: Beck Depression Inventory, NMSS TS: Non-Motor Symptoms Scale-Total Socre.

Figure 3.

Summary of the influences leading to impaired HRQoL in PD. HRQoL: health-related quality of life, PD: Parkinson’s disease, MDS UPDRS-IIII: Movement Disorder Society–Unified Parkinson’s Disease Rating Scale–Part III, LED: levodopa equivalent dose.

REFERENCES

• 1. Lubomski M, Rushworth RL, Tisch S. Hospitalisation and comorbidities in Parkinson’s disease: a large Australian retrospective study. J Neurol Neurosurg Psychiatry 2015;86:324–330.ArticlePubMed
• 2. Martinez-Martin P. What is quality of life and how do we measure it? Relevance to Parkinson’s disease and movement disorders. Mov Disord 2017;32:382–392.ArticlePubMed
• 3. Opara JA, Brola W, Leonardi M, Błaszczyk B. Quality of life in Parkinson’s disease. J Med Life 2012;5:375–381.PubMedPMC
• 4. Kelly DH, McGinley JL, Huxham FE, Menz HB, Watts JJ, Iansek R, et al. Health-related quality of life and strain in caregivers of Australians with Parkinson’s disease: an observational study. BMC Neurol 2012;12:57.ArticlePubMedPMC
• 5. Postuma RB, Aarsland D, Barone P, Burn DJ, Hawkes CH, Oertel W, et al. Identifying prodromal Parkinson’s disease: pre-motor disorders in Parkinson’s disease. Mov Disord 2012;27:617–626.ArticlePubMed
• 6. Soh SE, McGinley JL, Watts JJ, Iansek R, Morris ME. Health-related quality of life of australians with Parkinson disease: a comparison with international studies. Physiother Can 2012;64:338–346.ArticlePubMedPMC
• 7. Ravina B, Camicioli R, Como PG, Marsh L, Jankovic J, Weintraub D, et al. The impact of depressive symptoms in early Parkinson disease. Neurology 2007;69:342–347.ArticlePubMedPMC
• 8. Lubomski M, Tan AH, Lim SY, Holmes AJ, Davis RL, Sue CM. Parkinson’s disease and the gastrointestinal microbiome. J Neurol 2020;267:2507–2523.ArticlePubMed
• 9. Valles-Colomer M, Falony G, Darzi Y, Tigchelaar EF, Wang J, Tito RY, et al. The neuroactive potential of the human gut microbiota in quality of life and depression. Nat Microbiol 2019;4:623–632.ArticlePubMed
• 10. Lubomski M, Davis RL, Sue CM. The gut microbiota: a novel therapeutic target in Parkinson’s disease? Parkinsonism Relat Disord 2019;66:265–266.ArticlePubMed
• 11. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson’s Disease Questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing 1997;26:353–357.ArticlePubMed
• 12. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473–483.PubMed
• 13. Lubomski M, Louise Rushworth R, Lee W, Bertram KL, Williams DR. Sex differences in Parkinson’s disease. J Clin Neurosci 2014;21:1503–1506.ArticlePubMed
• 14. Lubomski M, Rushworth RL, Lee W, Bertram K, Williams DR. A cross-sectional study of clinical management, and provision of health services and their utilisation, by patients with Parkinson’s disease in urban and regional Victoria. J Clin Neurosci 2013;20:102–106.ArticlePubMed
• 15. Bucks RS, Cruise KE, Skinner TC, Loftus AM, Barker RA, Thomas MG. Coping processes and health-related quality of life in Parkinson’s disease. Int J Geriatr Psychiatry 2011;26:247–255.ArticlePubMed
• 16. Lubomski M, Davis RL, Sue CM. Gastrointestinal dysfunction in Parkinson’s disease. J Neurol 2020;267:1377–1388.ArticlePubMed
• 17. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–184.ArticlePubMedPMC
• 18. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561–571.ArticlePubMed
• 19. Visser M, Leentjens AF, Marinus J, Stiggelbout AM, van Hilten JJ. Reliability and validity of the Beck depression inventory in patients with Parkinson’s disease. Mov Disord 2006;21:668–672.ArticlePubMed
• 20. Schrag A, Barone P, Brown RG, Leentjens AF, McDonald WM, Starkstein S, et al. Depression rating scales in Parkinson’s disease: critique and recommendations. Mov Disord 2007;22:1077–1092.ArticlePubMedPMC
• 21. Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, et al. The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord 2007;22:1901–1911.ArticlePubMed
• 22. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129–2170.ArticlePubMed
• 23. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 2010;25:2649–2653.ArticlePubMed
• 24. Sateia MJ. International Classification of Sleep Disorders-third edition: highlights and modifications. Chest 2014;146:1387–1394.ArticlePubMed
• 25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013.
• 26. Moayyedi P, Duffett S, Braunholtz D, Mason S, Richards ID, Dowell AC, et al. The Leeds Dyspepsia Questionnaire: a valid tool for measuring the presence and severity of dyspepsia. Aliment Pharmacol Ther 1998;12:1257–1262.ArticlePubMed
• 27. Sood R, Ford AC. Diagnosis: Rome IV criteria for FGIDs - an improvement or more of the same? Nat Rev Gastroenterol Hepatol 2016;13:501–502.ArticlePubMed
• 28. Agachan F, Chen T, Pfeifer J, Reissman P, Wexner SD. A constipation scoring system to simplify evaluation and management of constipated patients. Dis Colon Rectum 1996;39:681–685.ArticlePubMed
• 29. Hagströmer M, Oja P, Sjöström M. The International Physical Activity Questionnaire (IPAQ): a study of concurrent and construct validity. Public Health Nutr 2006;9:755–762.ArticlePubMed
• 30. Winter Y, von Campenhausen S, Arend M, Longo K, Boetzel K, Eggert K, et al. Health-related quality of life and its determinants in Parkinson’s disease: results of an Italian cohort study. Parkinsonism Relat Disord 2011;17:265–269.ArticlePubMed
• 31. Soh SE, Morris ME, Watts JJ, McGinley JL, Iansek R. Health-related quality of life in people with Parkinson’s disease receiving comprehensive care. Aust Health Rev 2016;40:613–618.ArticlePubMed
• 32. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR; NMSS Validation Group. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord 2011;26:399–406.ArticlePubMed
• 33. Postuma RB, Gagnon JF, Vendette M, Charland K, Montplaisir J. Manifestations of Parkinson disease differ in association with REM sleep behavior disorder. Mov Disord 2008;23:1665–1672.ArticlePubMed
• 34. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study. Brain 2000;123:2297–2305.PubMed
• 35. Ellis T, Boudreau JK, DeAngelis TR, Brown LE, Cavanaugh JT, Earhart GM, et al. Barriers to exercise in people with Parkinson disease. Phys Ther 2013;93:628–636.ArticlePubMedPMC
• 36. Cusso ME, Donald KJ, Khoo TK. The impact of physical activity on nonmotor symptoms in Parkinson’s disease: a systematic review. Front Med (Lausanne) 2016;3:35.ArticlePubMedPMC
• 37. Wu PL, Lee M, Huang TT. Effectiveness of physical activity on patients with depression and Parkinson’s disease: a systematic review. PLoS One 2017;12:e0181515.ArticlePubMedPMC
• 38. Choi SM, Kim BC, Jung HJ, Yoon GJ, Kang KW, Choi KH, et al. Impact of pain and pain subtypes on the quality of life of patients with Parkinson’s disease. J Clin Neurosci 2017;45:105–109.ArticlePubMed
• 39. Mylius V, Ciampi de Andrade D, Cury RG, Teepker M, Ehrt U, Eggert KM, et al. Pain in Parkinson’s disease: current concepts and a new diagnostic algorithm. Mov Disord Clin Pract 2015;2:357–364.ArticlePubMedPMC
• 40. Poirier AA, Aubé B, Côté M, Morin N, Di Paolo T, Soulet D. Gastrointestinal dysfunctions in Parkinson’s disease: symptoms and treatments. Parkinsons Dis 2016;2016:6762528.ArticlePubMedPMC
• 41. Pachana NA, Egan SJ, Laidlaw K, Dissanayaka N, Byrne GJ, Brockman S, et al. Clinical issues in the treatment of anxiety and depression in older adults with Parkinson’s disease. Mov Disord 2013;28:1930–1934.ArticlePubMed
• 42. Schrag A, Jahanshahi M, Quinn NP. What contributes to depression in Parkinson’s disease? Psychol Med 2001;31:65–73.ArticlePubMed

Figure & Data

References

Citations

Citations to this article as recorded by  

• Risk factors and intervention of caregiver burden in Parkinson’s disease: a systematic review and meta-analysis
  Yan Zhao, Wenxiang Wu, Jianjun Wu, Bin Shen, Yanpei Cao, Yafang Xu
  Quality of Life Research.2024; 33(7): 1753.     CrossRef
• Health-related quality of life in Parkinson’s disease: systematic review and meta-analysis of EuroQol (EQ-5D) utility scores
  Raghu Bhanupriya, Madhumitha Haridoss, Goda Suchitra Lakshmi, Bhavani Shankara Bagepally
  Quality of Life Research.2024; 33(7): 1781.     CrossRef
• Factors associated with self-rated health in people with late-stage parkinson’s and cognitive impairment
  Jennifer S. Pigott, Megan Armstrong, Nathan Davies, Daniel Davis, Bastiaan R. Bloem, Stefan Lorenzl, Wassilios G. Meissner, Per Odin, Joaquim J. Ferreira, Richard Dodel, Anette Schrag
  Quality of Life Research.2024; 33(9): 2439.     CrossRef
• Understanding what aspects of Parkinson’s disease matter most to patients and families
  Jennifer R. Mammen, Mirinda Tyo, Joyce Cadorette, Jamie L. Adams, Yuge Xiao, Diane Stephenson, Claire Bale
  Scientific Reports.2024;[Epub]     CrossRef
• Impact of advanced Parkinson’s disease on caregivers: an international real-world study
  Pablo Martinez-Martin, Matej Skorvanek, Tove Henriksen, Susanna Lindvall, Josefa Domingos, Ali Alobaidi, Prasanna L. Kandukuri, Vivek S. Chaudhari, Apeksha B. Patel, Juan Carlos Parra, James Pike, Angelo Antonini
  Journal of Neurology.2023; 270(4): 2162.     CrossRef
• Perspectives of people with Parkinson's disease and family carers about disease management in community settings: A cross‐country qualitative study
  M. Victoria Navarta‐Sánchez, Ana Palmar‐Santos, Azucena Pedraz‐Marcos, Claire Reidy, Dia Soilemezi, Anita Haahr, Dorthe Sørensen, Helle Rønn Smidt, Line Kildal Bragstad, Ellen Gabrielsen Hjelle, Silje Bjørnsen Haavaag, Mari Carmen Portillo
  Journal of Clinical Nursing.2023; 32(15-16): 5201.     CrossRef
• Barriers to home exercise for patients with Parkinson’s disease: a qualitative study
  Qiaohong Wang, Yiping Chen, Linbo Li, Chao Li, Li Li, Huili Cao, Hui Yang
  BMJ Open.2023; 13(2): e061932.     CrossRef
• An update on pathogenesis and clinical scenario for Parkinson’s disease: diagnosis and treatment
  Hussaini Adam, Subash C. B. Gopinath, M. K. Md Arshad, Tijjani Adam, N. A. Parmin, Irzaman Husein, Uda Hashim
  3 Biotech.2023;[Epub]     CrossRef
• Gastrointestinal Dysfunction in Parkinson’s Disease: Neuro-Gastroenterology Perspectives on a Multifaceted Problem
  Ai Huey Tan, Kee Huat Chuah, Yuan Ye Beh, Jie Ping Schee, Sanjiv Mahadeva, Shen-Yang Lim
  Journal of Movement Disorders.2023; 16(2): 138.     CrossRef
• Abdominal pain in Parkinson’s disease
  A.A. Pilipovich, O.V. Vorobyova, S.A. Makarov
  Russian Journal of Pain.2023; 21(2): 12.     CrossRef
• The multifaceted impact of structured training program on persons with Parkinson disease and their adult caregiver: A protocol for a systematic review
  Sharmila Gopala Krishna Pillai, Nor Azlin Mohd Nordin, Norlinah Mohamed Ibrahim
  Medicine.2023; 102(28): e33966.     CrossRef
• Detecting Minor Symptoms of Parkinson’s Disease in the Wild Using Bi-LSTM with Attention Mechanism
  Vasileios Skaramagkas, Iro Boura, Cleanthi Spanaki, Emilia Michou, Georgios Karamanis, Zinovia Kefalopoulou, Manolis Tsiknakis
  Sensors.2023; 23(18): 7850.     CrossRef
• Lower gastrointestinal dysfunction in patients with Parkinson’s disease
  A.A. Pilipovich, O.V. Vorob’eva, S.A. Makarov, A.V. Kuchuk
  Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova.2023; 123(12): 42.     CrossRef
• The impact of device-assisted therapies on the gut microbiome in Parkinson’s disease
  Michal Lubomski, Xiangnan Xu, Andrew J. Holmes, Jean Y. H. Yang, Carolyn M. Sue, Ryan L. Davis
  Journal of Neurology.2022; 269(2): 780.     CrossRef
• Predictive Model of Quality of Life in Patients with Parkinson’s Disease
  Eduardo Candel-Parra, María Pilar Córcoles-Jiménez, Victoria Delicado-Useros, Marta Carolina Ruiz-Grao, Antonio Hernández-Martínez, Milagros Molina-Alarcón
  International Journal of Environmental Research and Public Health.2022; 19(2): 672.     CrossRef
• Die neue Parkinson-Schmerzklassifikation (PSK)
  V. Mylius, S. Perez Lloret, C. S. Brook, M. T. Krüger, S. Hägele-Link, R. Gonzenbach, J. Kassubek, S. Bohlhalter, J. P. Lefaucheur, L. Timmermann, G. Kägi, F. Brugger, D. Ciampi de Andrade, J. C. Möller
  Der Nervenarzt.2022; 93(10): 1019.     CrossRef
• Quantification Analysis of Sleep Based on Smartwatch Sensors for Parkinson’s Disease
  Yi-Feng Ko, Pei-Hsin Kuo, Ching-Fu Wang, Yu-Jen Chen, Pei-Chi Chuang, Shih-Zhang Li, Bo-Wei Chen, Fu-Chi Yang, Yu-Chun Lo, Yi Yang, Shuan-Chu Vina Ro, Fu-Shan Jaw, Sheng-Huang Lin, You-Yin Chen
  Biosensors.2022; 12(2): 74.     CrossRef
• Gastrointestinal Dysfunction Impact on Life Quality in a Cohort of Russian Patients with Parkinson’s Disease I-III H&Y Stage
  A. A. Pilipovich, O. V. Vorob’eva, S. A. Makarov, N. N. Shindryaeva, Yu D. Vorob’eva, Seyed-Mohammad Fereshtehnejad
  Parkinson's Disease.2022; 2022: 1.     CrossRef
• Nutritional Intake and Gut Microbiome Composition Predict Parkinson’s Disease
  Michal Lubomski, Xiangnan Xu, Andrew J. Holmes, Samuel Muller, Jean Y. H. Yang, Ryan L. Davis, Carolyn M. Sue
  Frontiers in Aging Neuroscience.2022;[Epub]     CrossRef
• The Gut Microbiome in Parkinson’s Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies
  Michal Lubomski, Xiangnan Xu, Andrew J. Holmes, Samuel Muller, Jean Y. H. Yang, Ryan L. Davis, Carolyn M. Sue
  Frontiers in Aging Neuroscience.2022;[Epub]     CrossRef
• Characteristics and quality of life of substance users and their caregivers
  Jadranka M. Maksimovic, Olivera B. Sbutega, Aleksandar D. Pavlovic, Hristina D. Vlajinac, Ivana I. Kavecan, Isidora S. Vujcic, Sandra B. Grujicic Sipetic
  Medicine.2022; 101(31): e29699.     CrossRef
• Defining the unknowns for cell therapies in Parkinson's disease
  Emma L. Lane, Mariah J. Lelos
  Disease Models & Mechanisms.2022;[Epub]     CrossRef
• Increased Added Sugar Consumption Is Common in Parkinson's Disease
  Natalie C. Palavra, Michal Lubomski, Victoria M. Flood, Ryan L. Davis, Carolyn M. Sue
  Frontiers in Nutrition.2021;[Epub]     CrossRef
• Relationship Satisfaction in People with Parkinson’s Disease and Their Caregivers: A Cross-Sectional Observational Study
  Johanne Heine, Hannah von Eichel, Selma Staege, Günter U. Höglinger, Florian Wegner, Martin Klietz
  Brain Sciences.2021; 11(6): 822.     CrossRef
• Diagnosis and Management of Pain in Parkinson's Disease: A New Approach
  Veit Mylius, Jens Carsten Möller, Stephan Bohlhalter, Daniel Ciampi de Andrade, Santiago Perez Lloret
  Drugs & Aging.2021; 38(7): 559.     CrossRef
• Cognitive Influences in Parkinson's Disease Patients and Their Caregivers: Perspectives From an Australian Cohort
  Michal Lubomski, Ryan L. Davis, Carolyn M. Sue
  Frontiers in Neurology.2021;[Epub]     CrossRef

Comments on this article